17-AAG is an inhibitor of heat shock protein 90 (Hsp90) and a derivative of geldanamycin (Cay-13355) that selectively inhibits BT474 tumor cell Hsp90 over fibroblast Hsp90 (IC50s = 5 and 943 nM, respectively). It inhibits the growth of prostate cancer cell lines (IC50s = 25-45 nM) and promotes the degradation of...

Potent, less toxic analog of geldanamycin, Inhibits the essential ATPase activity of HSP90, Telomerase activity inhibitor, Apoptosis inducer, Antitumor compound. Semi-synthetic derivative from geldanamycin.

An anologue of geldanamycin. It is a Hsp90 antagonist that induces apoptosis in human leukemiacells. It has been shown to enhance paclitaxel-mediated cytotoxicity and downregulate vascular endothelial factor expression.

Semi-synthetic derivative of geldanamycin, demonstrating greater stability and lower in vivo toxicity than its parent compound. 17-AAG binds specifically to heat shock protein Hsp90 in a manner similar to geldanamycin, but the binding is weaker. Solubility: Soluble in DMSO at 150mg/ml, soluble in ethanol at 5mg/ml,...